---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-043485"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2025-03-24T23:59:59+00:00"
generated_at: "2026-05-24T06:57:24.945972+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lexeo Q4 net loss $25.9M; FDA aligns on LX2006 accelerated path; LX2020 shows protein expression increases

## Summary
- Net loss $25.9M ($0.78/sh) for Q4 2024 vs $14.2M; FY net loss $98.3M ($3.09/sh) vs $66.4M.
- Cash $128.5M expected to fund operations into 2027.
- FDA agrees to use frataxin expression increase from baseline as co-primary endpoint for LX2006 pivotal study.
- LX2020 cohort 1: PKP2 protein increased 71% and 115% from baseline; first participant saw 67% PVC reduction.
- LX2020 cohort 2 fully enrolled; interim clinical data expected H2 2025.

## SEC filing metadata
- accession: 0000950170-25-043485
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2025-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000095017025043485/0000950170-25-043485-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000095017025043485/lxeo-20250324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-043485
- JSON: https://secwatch.observer/filing/0000950170-25-043485.json
- Plain text: https://secwatch.observer/filing/0000950170-25-043485.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.